Genetics of cerebrovascular disorders

Mayo Clinic Proceedings

Volumn 80, Issue 1, 2005, Pages 122-132

  Meschia, James F ^a   Brott, Thomas G ^a   Brown Jr , Robert D ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GALACTOSIDASE; ANTITHROMBOCYTIC AGENT; ARGININE; BETAINE; CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HYDROXYUREA; INTEGRIN RECEPTOR; INTEGRIN RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; PYRIDOXINE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

AUTOSOMAL DOMINANT DISORDER; BLOOD FLOW; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN VEIN; CADASIL; CARNEY COMPLEX; CEREBRAL CAVERNOUS MALFORMATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CEREBROVASCULAR MALFORMATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONSULTATION; CONVULSION; CYSTATIN C RELATED FAMILIAL CEREBRAL AMYLOID ANGIOPATHY; DIAGNOSTIC ACCURACY; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FABRY DISEASE; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILY HISTORY; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETICS; HEREDITARY CEREBRAL HEMORRHAGE WITH AMYLOIDOSIS OF THE DUTCH TYPE; HEREDITARY ENDOTHELIOPATHY WITH RETINOPATHY, NEPHROPATHY AND STROKE; HOMOCYSTINURIA; HUMAN; INTRACRANIAL ANEURYSM; KIDNEY POLYCYSTIC DISEASE; MELAS SYNDROME; MOYAMOYA DISEASE; NEUROLOGIC DISEASE; PEDIGREE; PROGNOSIS; RENDU OSLER WEBER DISEASE; SICKLE CELL ANEMIA; STROKE; VASCULAR AMYLOIDOSIS; VEIN THROMBOSIS;

EID: 11344261990     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62969-8     Document Type: Conference Paper

References (89)

1. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke. 2002;33:769-774.
2. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke. 1992;23:221-223.
3. Caicoya M, Corrales C, Rodriguez T. Family history and stroke: a community case-control study in Asturias, Spain. J Epidemiol Biostat. 1999;4:313-320.
4. Liao D, Myers R, Hunt S, et al. Familial history of stroke and stroke risk: The Family Heart Study. Stroke. 1997;28:1908-1912.
5. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke: the Framingham Study. Stroke. 1993;24:1366-1371.
6. Markus HS, ed. Stroke Genetics. Oxford, England: Oxford University Press; 2003.
7. Hamosh A, Scott AF, Amberger J, Bocchini C, Valle D, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2002;30:52-55.
8. Gordon H. The family history and the pedigree chart. Postgrad Med. 1972;52:123-125.
9. Kinmonth AL, Reinhard J, Bobrow M, Pauker S. The new genetics: implications for clinical services in Britain and the United States. BMJ. 1998;316:767-770.
10. Ciarleglio LJ, Bennett KL, Williamson J, Mandell JB, Marks JH. Genetic counseling throughout the life cycle. J Clin Invest. 2003;112:1280-1286.
11. Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve. 2002;26:622-629.
12. Yoshikawa H, Ogawa I. Clinical diagnosis of Fabry disease: whorl-like corneal opacity. Neurology. 2003;60:1048.
13. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998;42:360-366.
14. Mohanraj R, Leach JP, Broome JC, Smith DF. Neurological presentation of Fabry's disease in a 52 year old man. J Neurol Neurosurg Psychiatry. 2002;73:340-342.
15. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-242.
16. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338-346.
17. Grewal RP. Stroke in Fabry's disease. J Neurol. 1994;241:153-156.
18. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol. 1996;40:8-17.
19. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
20. Utsumi K, Yamamoto N, Kase R, et al. High incidence of thrombosis in Fabry's disease. Intern Med. 1997;36:327-329.
21. Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease [published correction appears in JAMA. 2001;285:169]. JAMA. 2000;284:2771-2775.
22. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16:481-488.
23. Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol. 1994;9:4-13.
24. Ko CH, Lam CW, Tse PW, Kong CK, Chan AK, Wong LJ. De novo mutation in the mitochondrial tRNALeu(UUR) gene (A3243G) with rapid segregation resulting in MELAS in the offspring. J Paediatr Child Health. 2001;37:87-90.
25. Pang CY, Huang CC, Yen MY, et al. Molecular epidemiologic study of mitochondrial DNA mutations in patients with mitochondrial diseases in Taiwan. J Formos Med Assoc. 1999;98:326-334.
26. Nishino I, Komatsu M, Kodama S, Horai S, Nonaka I, Goto Y. The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Muscle Nerve. 1996;19:1603-1604.
27. Sato W, Hayasaka K, Shoji Y, et al. A mitochondrial tRNA(Leu)(UUR) mutation at 3,256 associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Biochem Mol Biol Int. 1994;33:1055-1061.
28. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta. 1995;1271:275-280.
29. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997;156:562-564.
30. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348:2656-2668.
31. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707-710.
32. Lardelli M, Dahlstrand J, Lendahl U. The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium. Mech Dev. 1994;46:123-136.
33. Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350:1511-1515.
34. Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105:597-605.
35. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol. 2000;47:388-391.
36. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731-739.
37. Walsh JS, Perniciaro C, Meschia JF. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy): diagnostic skin biopsy changes determined by electron microscopy. J Am Acad Dermatol. 2000;43:1125-1127.
38. Mayer M, Straube A, Bruening R, et al. Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL. J Neurol. 1999;246:526-532.
39. de Freitas GR, Miklossy J, Christen-Zach S, Reichhart M, Bogousslavsky J. A CADASIL case with normal skin biopsy and without mutations in exons 3 and 4 of the Notch3 gene. J Neurol Sci. 2001;193:43-47.
40. Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358: 2049-2051.
41. Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke. 2002;33:67-71.
42. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
43. Nichols FT, Jones AM, Adams RJ. Stroke Prevention in Sickle Cell Disease (STOP) study guidelines for transcranial Doppler testing. J Neuroimaging. 2001;11:354-362.
44. Adams RJ. Lessons from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study. J Child Neurol. 2000;15:344-349.
45. Pegelow CH, Wang W, Granger S, et al. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol. 2001;58:2017-2021.
46. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. Sickle cell disease: the neurological complications. Ann Neurol. 2002;51:543-552.
47. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment [published correction appears in JAMA. 2003;290:756]. JAMA. 2003;289:1645-1651.
48. Carreiro-Lewandowski E. Newborn screening: an overview. Clin Lab Sci. 2002;15:229-238.
49. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86:4041-4046.
50. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet. 2000;9:3037-3046.
51. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
52. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
53. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP, Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions [published correction appears in BMJ. 1998;316:822]. BMJ. 1998;316:589-592.
54. Revesz T, Holton JL, Lashley T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002;12:343-357.
55. Calero M, Pawlik M, Soto C, et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J Neurochem. 2001;77:628-637.
56. Olafsson E, Hauser WA. Prevalence of epilepsy in rural Iceland: a population-based study. Epilepsia. 1999;40:1529-1534.
57. Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol. 1999;56:1152-1155.
58. Uitti RJ, Donat JR, Rozdilsky B, Schneider RJ, Koeppen AH. Familial oculoleptomeningeal amyloidosis: report of a new family with unusual features. Arch Neurol. 1988;45:1118-1122.
59. Sakashita N, Ando Y, Jinnouchi K, et al. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int. 2001;51:476-480.
60. Ellie E, Camou F, Vital A, et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology. 2001;57:135-137.
61. Schievink WI, Schaid DJ, Michels VV, Piepgras DG. Familial aneurysmal subarachnoid hemorrhage: a community-based study. J Neurosurg. 1995; 83:426-429.
62. De Braekeleer M, Perusse L, Cantin L, Bouchard JM, Mathieu J. A study of inbreeding and kinship in intracranial aneurysms in the Saguenay Lac-Saint-Jean region (Quebec, Canada). Ann Hum Genet. 1996;60(pt 2):99-104.
63. Wang PS, Longstreth WT Jr, Koepsell TD. Subarachnoid hemorrhage and family history: a population-based case-control study. Arch Neurol. 1995;52:202-204.
64. Kissela BM, Sauerbeck L, Woo D, et al. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke. 2002;33:1321-1326.
65. McConnell RS, Rubinsztein DC, Fannin TF, et al. Autosomal dominant polycystic kidney disease unlinked to the PKD1 and PKD2 loci presenting as familial cerebral aneurysm [letter]. J Med Genet. 2001;38:238-240.
66. Belz MM, Hughes RL, Kaehny WD, et al. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2001;38:770-776.
67. Nakajima F, Shibahara N, Arai M, Gohji K, Ueda H, Katsuoka Y. Intracranial aneurysms and autosomal dominant polycystic kidney disease: followup study by magnetic resonance angiography. J Urol. 2000;164:311-313.
68. Mariani L, Bianchetti MG, Schroth G, Seiler RW. Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease - to screen, to clip, to coil? Nephrol Dial Transplant. 1999;14:2319-2322.
69. Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations: incidence and familial occurrence. N Engl J Med. 1988;319:343-347.
70. Labauge P, Laberge S, Brunereau L, Levy C, Tournier-Lasserve E. Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families. Lancet. 1998;352:1892-1897.
71. Verlaan DJ, Davenport WJ, Stefan H, Sure U, Siegel AM, Rouleau GA. Cerebral cavernous malformations: mutations in Krit1. Neurology. 2002;58:853-857.
72. McAllister KA, Lennon F, Bowles-Biesecker B, et al. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet. 1994;31:927-932,
73. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189-195.
74. Amin-Hanjani S. The genetics of cerebrovascular malformations. Semin Cerebrovasc Dis Stroke. 2002;2:73-81.
75. Maher CO, Piepgras DG, Brown RD Jr, Friedman JA, Pollock BE. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke. 2001;32:877-882.
76. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. Neuropathology. 2000;20(suppl):S61-S64.
77. Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000;31:930-935.
78. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99:3144-3150.
79. Houkin K, Tanaka N, Takahashi A, Kamiyama H, Abe H, Kajii N. Familial occurrence of moyamoya disease: magnetic resonance angiography as a screening test for high-risk subjects. Childs Nerv Syst. 1994;10:421-425.
80. Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet. 2001;69:447-453.
81. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology. 1997;49:1322-1330.
82. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke, 2004;35:212-227.
83. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000;123(pt 9):1784-1812.
84. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131-138.
85. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
86. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol. 2002;156:311-318.
87. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet. 2002;70:593-603.
88. Meschia JF, Brown RD Jr, Brott TG, Chukwudelunzu FE, Hardy J, Rich SS. The Siblings With Ischemic Stroke Study (SWISS) Protocol. BMC Med Genet. 2002;3:1.
89. Meschia JF, Brott TG, Brown RD Jr, et al. The Ischemic Stroke Genetics Study (ISGS) protocol. BMC Neurol. 2003;3:4.